Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 12:55 am EST
Share
Seegene, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 91,886.24 million compared to KRW 150,844.1 million a year ago. Net loss was KRW 4,676.52 million compared to KRW 11,069.48 million a year ago. Basic loss per share from continuing operations was KRW 101 compared to KRW 217 a year ago. Basic loss per share was KRW 101 compared to KRW 217 a year ago.
For the nine months, sales was KRW 266,863.67 million compared to KRW 730,736.29 million a year ago. Net loss was KRW 5,164.13 million compared to net income of KRW 179,552.66 million a year ago. Basic loss per share from continuing operations was KRW 109 compared to basic earnings per share from continuing operations of KRW 3,523 a year ago. Basic loss per share was KRW 109 compared to basic earnings per share of KRW 3,523 a year ago.
Seegene Inc is a Korea-based company engaged in the development, manufacturing and distribution of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products. In addition, it is involved in the provision of automatic real-time detection instruments. The Company provides its products under the brand names of Seeplex, Anyplex and Magicplex. The Company distributes its products within domestic market and to overseas markets.
SEEGENE, INC. 
